Clinical phenotypes of Italian and Spanish patients with &agr;1-antitrypsin deficiency

With the aim of providing better clinical characterisation of patients with &agr;1-antitrypsin deficiency (AATD), we analysed the data of adult patients with severe AATD enrolled in the Spanish and Italian national registries. We assessed 745 subjects, 416 of whom were enrolled in the Spanish registry and 329 in the Italian registry. 57.2% were male and 64.9% were smokers or former smokers with a mean±sd age of 49.9±13.8 years. Most (81.2%) were index cases, mainly having the PI*ZZ genotype (73.4%), and the mean±sd diagnostic delay was 9.0±12.1 years. Patients with chronic bronchitis were younger, had better preserved lung function and lower tobacco consumption. Overlap patients (chronic obstructive pulmonary disease with asthma) were mainly females, more frequently never-smokers and received respiratory medications more often. 48% of emphysema, 27.5% of chronic bronchitis and 44.8% of overlap subjects were receiving augmentation therapy. Compared with PI*ZZ patients (n=547), the PI*SZ (n=124) subjects were older at diagnosis and had more preserved lung function, despite a higher mean smoking consumption. Early diagnosis of AATD is still an unmet need. Augmentation therapy is administered to similar proportions of patients with different clinical phenotypes. PI*ZZ patients in both registries had more severe respiratory disease than those with PI*SZ, despite lower smoking levels.

[1]  Centro Andaluz de Documentación e Información de Medicamentos.  Tratamiento farmacológico de la EPOC estable , 2014 .

[2]  P. Casán,et al.  Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). , 2013, Archivos de bronconeumologia.

[3]  C. Laurell,et al.  The Electrophoretic α1-Globulin Pattern of Serum in α1-Antitrypsin Deficiency , 2013, COPD.

[4]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[5]  J. Stoller,et al.  A review of α1-antitrypsin deficiency. , 2012, American journal of respiratory and critical care medicine.

[6]  J. Soriano,et al.  Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD , 2012 .

[7]  C. Vogelmeier,et al.  Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. , 2012, Respiratory medicine.

[8]  A. von Eckardstein,et al.  Serum levels and genotype distribution of α1-antitrypsin in the general population , 2012, Thorax.

[9]  M. Miravitlles,et al.  Clinical Phenotypes of COPD: Identication, Denition and Implications for Guidelines , 2012 .

[10]  M. Miravitlles,et al.  Rare alpha-1-antitrypsin variants: are they really so rare? , 2012, Therapeutic advances in respiratory disease.

[11]  田中 俊典.  National Center for Biotechnology Information (NCBI) , 2012 .

[12]  M. Miravitlles,et al.  Factors Associated With the Evolution of Lung Function in Patients With Alpha-1 Antitrypsin Deficiency in the Spanish Registry , 2011 .

[13]  Joyce D. Schroeder,et al.  The clinical features of the overlap between COPD and asthma , 2011, Respiratory research.

[14]  M. Miravitlles,et al.  Registros de enfermedades respiratorias en España: fundamentos y organización , 2011 .

[15]  Ignacio Blanco,et al.  [Respiratory disease registries in Spain: fundamentals and organization]. , 2011, Archivos de Bronconeumologia.

[16]  M. Miravitlles,et al.  The IDDEA project: a strategy for the detection of alpha-1 antitrypsin deficiency in COPD patients in the primary care setting , 2011, Therapeutic advances in respiratory disease.

[17]  P. Barnes,et al.  The Future of COPD , 2011 .

[18]  M. Miravitlles,et al.  Factors associated with the evolution of lung function in patients with alpha-1 antitrypsin deficiency in the Spanish registry. , 2011, Archivos de bronconeumologia.

[19]  Edwin K Silverman,et al.  Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.

[20]  T. Welte,et al.  Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency , 2010, Therapeutic advances in respiratory disease.

[21]  A. Tonelli,et al.  Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies , 2010, Therapeutic advances in respiratory disease.

[22]  M. Miravitlles,et al.  Laboratory testing of individuals with severe α1-antitrypsin deficiency in three European centres , 2010, European Respiratory Journal.

[23]  A. Agustí,et al.  Fenotipos clnicos de la EPOC , 2010 .

[24]  R. Stockley,et al.  CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. , 2009, Chest.

[25]  G. Rachelefsky,et al.  Issues in the diagnosis of alpha 1-antitrypsin deficiency. , 2008, The Journal of allergy and clinical immunology.

[26]  R. Stockley,et al.  Prevalence and Impact of Bronchiectasis in α1-Antitrypsin Deficiency , 2007 .

[27]  M. Zorzetto,et al.  Laboratory diagnosis of alpha1-antitrypsin deficiency. , 2007, Translational research : the journal of laboratory and clinical medicine.

[28]  M. Miravitlles,et al.  Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency , 2007, International journal of chronic obstructive pulmonary disease.

[29]  R. Stockley,et al.  Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development , 2007, European Respiratory Journal.

[30]  M. Miravitlles,et al.  Guidelines for the Diagnosis and Management of α1-Antitrypsin Deficiency , 2006 .

[31]  R. Vidal,et al.  Diagnóstico y tratamiento del déficit de alfa-1-antitripsina , 2006 .

[32]  F. D. de Serres,et al.  Estimated numbers and prevalence of PI*S and PI*Z alleles of α1-antitrypsin deficiency in European countries , 2006, European Respiratory Journal.

[33]  M. Miravitlles,et al.  Results of a case-detection programme for α1-antitrypsin deficiency in COPD patients , 2005, European Respiratory Journal.

[34]  C. Strange,et al.  Delay in Diagnosis of α1-Antitrypsin Deficiency: A Continuing Problem , 2005 .

[35]  E. Silverman,et al.  The protease inhibitor PI*S allele and COPD: a meta-analysis , 2005, European Respiratory Journal.

[36]  J. Stoller,et al.  A Review of Alpha-1 Antitrypsin Deficiency , 2005, COPD.

[37]  C. Tinelli,et al.  Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency , 2005, Journal of Medical Genetics.

[38]  A. Dirksen,et al.  American Thoracic Society/European Respiratory Society: Standards in Diagnostik und Therapie bei Patienten mit Alpha-1-Antitrypsin-Mangel , 2005 .

[39]  C. Strange,et al.  Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. , 2005, Chest.

[40]  J. Stoller.  Erratum: ATS/ERS Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency (American Journal of Respiratory and Critical Care Medicine (835)) , 2004 .

[41]  N. Seersholm,et al.  α1-Antitrypsin deficiency · 1: Epidemiology of α1-antitrypsin deficiency , 2004, Thorax.

[42]  R. Pauwels,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Updated 2003 , 2004, COPD.

[43]  Thomas,et al.  The Spanish experience , 2004 .

[44]  American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. , 2003, American journal of respiratory and critical care medicine.

[45]  L. Fleming,et al.  Formation and Current Results of a Patient-Organized Registry for α1-Antitrypsin Deficiency , 2000 .

[46]  L. Fleming,et al.  Formation and current results of a patient-organized registry for alpha(1)-antitrypsin deficiency. , 2000, Chest.

[47]  B. Balbi,et al.  A national program for detection of α1-antitrypsin deficiency in Italy , 1999 .

[48]  B. Balbi,et al.  A national program for detection of alpha 1-antitrypsin deficiency in Italy. Gruppo I.D.A. , 1999, Respiratory medicine.

[49]  M. Miravitlles,et al.  Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience. , 1998, Respiratory medicine.

[50]  M. Schluchter,et al.  Baseline Characteristics of Enrollees in the National Heart, Lung and Blood Institute Registry of α1-Antitrypsin Deficiency , 1997 .

[51]  M. Schluchter,et al.  Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. , 1997, Chest.

[52]  Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. , 1997, Bulletin of the World Health Organization.

[53]  A. Dirksen,et al.  Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. , 1994, Thorax.

[54]  Penny Levene.  The Spanish experience , 1993 .

[55]  E. Silverman,et al.  Variability of pulmonary function in alpha-1-antitrypsin deficiency: residual family resemblance beyond the effect of the Pi locus. , 1990, Human heredity.

[56]  E. Silverman,et al.  Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. , 1989, Annals of internal medicine.

[57]  M. Zierski,et al.  Heterozygosity in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD). , 1985, European journal of respiratory diseases.

[58]  G. Feldmann,et al.  Antitrypsin deficiency. , 1973, Lancet.

[59]  C. Laurell,et al.  The Electrophoretic α;1-Globulin Pattern of Serum in α;1-Antitrypsin Deficiency , 1963 .